Synageva BioPharma (Waltham, MA) a clinical-stage biopharma and developer of the Synageva Expression Platform, an integrated platform of vectors and protein production, processing and purification systems used to develop their pipeline of monoclonal antibodies, cytokines, and biosimilars, closed a $33M Series X financing. Participants inlcude Baker Brothers Investments, Tullis Health Investors, Four Partners, Yasuda Enterprise Devlopment and Hunt BioVentures.

CORRECTION | Previously reported as a Series F financing.